Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced The Ministry of Health of Spain (MSCBS) has granted approval for the reimbursement o
Akcea Therapeutics Canada Confirms Letter of Intent with Pan-Canadian Pharmaceutical Alliance for TEGSEDI™ (inotersen injection)
12:00pm, Wednesday, 13'th May 2020
OTTAWA , May 13, 2020 /CNW/ - Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (AKCA), today announced that it has concluded its negotiation with the pan-Canadian Pharmaceut
Xconomy: Bio Roundup: Acquisitive Alexion, CRISPR on COVID, C. diff Success & More
02:33pm, Friday, 08'th May 2020
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open
Maintaining Our $58 FVE for Ionis Following In-Line Q1; Significant Year for Pipeline Advancement
10:03am, Friday, 08'th May 2020Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
11:00am, Thursday, 07'th May 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that Carla Poulson has joined the company as senior vice president and chief human r
Edited Transcript of IONS earnings conference call or presentation 6-May-20 3:30pm GMT
08:35am, Thursday, 07'th May 2020
Q1 2020 Ionis Pharmaceuticals Inc Earnings Call
Ionis Pharmaceuticals, Inc. (IONS) Q1 2020 Earnings Call Transcript
05:31am, Thursday, 07'th May 2020
IONS earnings call for the period ending March 31, 2020.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
01:45pm, Wednesday, 06'th May 2020
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 9.09% and -16.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ionis reports first quarter 2020 financial results and recent business achievements
11:00am, Wednesday, 06'th May 2020
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today reported its financial results for the first quarter of 2020 and recent business highlights.
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
12:00am, Wednesday, 06'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peak
(Biotech Stocks Hitting 52-week Highs May 5)
• Adverum Biotechnologies...
Akcea Reports Financial Results and Highlights for First Quarter 2020
08:05pm, Tuesday, 05'th May 2020
Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing medicines to treat patients with serious and rare diseases
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
11:05am, Friday, 01'st May 2020
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2020 Virtual Annual Meeting of Stockholders and provide a general corporate update on Thursday, June 4, 2020
Needham Believes Seattle Genetics (SGEN) Still Has Room to Grow
10:22am, Friday, 01'st May 2020
In a report released today, Chad Messer from Needham reiterated a Buy rating on Seattle Genetics (SGEN), with a price target of $163.00. The company's
Agios Pharma (AGIO) Gets a Buy Rating from Needham
03:27pm, Thursday, 30'th Apr 2020
In a report released today, Chad Messer from Needham maintained a Buy rating on Agios Pharma (AGIO), with a price target of $71.00. The company's shares
